Preventing Blood Clots in Pregnancy

Quick take: Blood clot prevention in pregnancy hinges on assessing your personal VTE (venous thromboembolism) risk, then matching that score to a low‑molecular‑weight heparin (LMWH) regimen that’s safe for you and your baby. Most pregnant people at moderate‑to‑high risk start enoxaparin or dalteparin at a prophylactic dose early in the second trimester, adjust the dose as they grow, pause 24 hours before planned delivery, and continue a short postpartum course. Talk with your provider about the exact score, dosing schedule, and any warning signs you should watch for.

It’s 2 a.m., you’ve just felt a flutter in your calf and wonder if it’s “just a cramp” or the first whisper of a blood clot. You’re not alone—many pregnant people wake up with a racing heart about clot risk, especially after hearing about a friend’s emergency. The good news is that clinicians have a clear, step‑by‑step system to gauge your risk, choose the right LMWH, and keep you safe from the first trimester through postpartum.

In this guide we’ll walk through every piece of the puzzle: the specific clot‑forming factors that pregnancy adds, how to calculate the RCOG‑based risk score, the exact LMWH doses recommended for each score and trimester, how to pick between enoxaparin and dalteparin, what to monitor, and how to transition off medication before labor. By the end you’ll have a concrete plan you can discuss with your obstetrician, complete with a handy table and a link to an online calculator.

Whether you’re a first‑time mom or have been through a high‑risk pregnancy before, you’ll find practical answers to the most common questions: “When should I start LMWH?”, “Do I need blood tests?”, and “What if I’m due for a C‑section?” Let’s turn uncertainty into a clear, doctor‑approved roadmap.

Why blood clots are a special concern in pregnancy

Pregnancy is a natural hypercoagulable state—your body deliberately shifts toward clotting to protect you from bleeding during delivery. Hormones like estrogen increase clot‑forming factors (fibrinogen, factor VII, VIII, and X) while reducing natural anticoagulants. Simultaneously, the growing uterus compresses pelvic veins, slowing blood flow in the legs and pelvis. These changes raise the baseline risk of venous thromboembolism (VTE) from about 1‑2 per 1,000 pregnancies to roughly 5‑6 per 1,000, according to the American College of Obstetricians and Gynecologists (ACOG).

Most VTE events are deep‑vein thromboses (DVT) in the leg, but a clot can travel to the lungs (pulmonary embolism), which is life‑threatening for both mother and baby. Recognizing who is most at risk lets clinicians intervene early with prophylactic LMWH, dramatically lowering the chance of a clot forming. The risk doesn’t disappear after delivery; the postpartum period carries the highest absolute VTE incidence, especially within the first six weeks, because the hypercoagulable state lingers while the uterus contracts back to its pre‑pregnancy size.

Key risk factors that stack on top of the pregnancy‑related changes include:

• Previous VTE or known thrombophilia (e.g., Factor V Leiden, prothrombin G20210A)
• Obesity (BMI ≥ 30 kg/m²)
• Age ≥ 35 years
• Multiple gestation (twins, triplets)
• Immobilization (extended bed rest, long‑haul travel)
• Cesarean delivery or planned surgical delivery
• Medical comorbidities (e.g., systemic lupus erythematosus, inflammatory bowel disease, cancer)
• Use of hormonal contraception immediately before conception

When several of these are present, the cumulative risk climbs sharply, and clinicians turn to a validated scoring system to decide on LMWH prophylaxis.

How to calculate a pregnancy clot risk score

1. List your personal risk factors. Write down any prior VTE, known thrombophilia, BMI, age, multiple gestation, and relevant medical conditions.
2. Assign points. Use the RCOG table:
   • Previous VTE – 3 points
   • Known thrombophilia – 2 points (3 points if high‑risk mutation)
   • Obesity (BMI ≥ 30) – 1 point
   • Age ≥ 35 – 1 point
   • Multiple pregnancy – 1 point
   • Immobilization – 1 point
   • Cesarean delivery (planned) – 1 point
   • Active inflammatory disease – 1 point
3. Sum the points. Add all the numbers you’ve assigned.
4. Interpret the total.
   • 0 – 1 point: Low risk – routine antenatal care.
   • 2 – 3 points: Moderate risk – consider prophylactic LMWH.
   • ≥ 4 points: High risk – prophylactic LMWH is strongly recommended.
5. Re‑evaluate each trimester. Some factors (e.g., BMI) may change, and new risk factors (like a surgical delivery plan) can emerge, so recalculate at the start of each trimester.

Because the math can feel tedious, you can use an online calculator for a quick check. Our own VTE Prophylaxis (RCOG) tool walks you through each item and instantly gives you a risk category.

Let’s look at a composite story that many readers share: Maya, 33, with a history of a DVT two years ago, is now pregnant with twins. She has a BMI of 32 and a planned C‑section. Adding her points—previous VTE (3) + thrombophilia (assuming none) + obesity (1) + age (1) + multiple gestation (1) + planned C‑section (1)—puts her at 7 points, classifying her as high risk. Her obstetrician started her on enoxaparin at 40 mg once daily from 12 weeks gestation, adjusting the dose later in the third trimester.

LMWH dosing basics by risk level and trimester

Low‑molecular‑weight heparin (LMWH) is the preferred prophylactic anticoagulant in pregnancy because it does not cross the placenta and has a predictable pharmacokinetic profile. The two most common brands are enoxaparin (Lovenox) and dalteparin (Fragmin). Dosing hinges on three variables: risk category, body weight (or BMI), and gestational age.

General dosing guidelines (prophylactic range):

• Low risk (0‑1 point): No routine LMWH; reassess if new risk factors appear.
• Moderate risk (2‑3 points): Enoxaparin 40 mg subcutaneously once daily OR dalteparin 5,000 units once daily, starting at 12‑14 weeks gestation.
• High risk (≥ 4 points): Enoxaparin 40 mg twice daily OR dalteparin 5,000 units twice daily, beginning as early as 10‑12 weeks if risk factors are present early.

Weight‑adjusted dosing is sometimes preferred for women with BMI ≥ 35 kg/m². In those cases, clinicians may calculate a dose of 0.5 mg/kg (enoxaparin) or 5 IU/kg (dalteparin) once daily, then increase to twice daily if the risk is high.

Because blood volume expands roughly 30 % by the third trimester, some providers raise the dose by 10‑20 % after 28 weeks. This adjustment is often guided by anti‑Xa level monitoring (target 0.2‑0.5 IU/mL for prophylaxis), especially in women with very high BMI or renal impairment.

Below is a concise table summarizing typical dosing schedules.

Always inject LMWH into the abdomen (at least 2 inches away from the umbilicus) or the outer thigh. Rotate sites daily to avoid bruising or lipohypertrophy. Consistent technique not only reduces local irritation but also helps maintain reliable absorption, which is critical for keeping your anti‑Xa level in the target range.

Choosing the right LMWH: enoxaparin vs. dalteparin

Both enoxaparin and dalteparin are safe in pregnancy, but subtle differences may influence your choice:

• Formulation: Enoxaparin is supplied as a pre‑filled syringe (often 40 mg/0.4 mL), while dalteparin comes in vials that require drawing up the exact unit dose.
• Renal clearance: Dalteparin has a slightly longer half‑life in patients with reduced kidney function, so dose adjustments may be needed if creatinine clearance falls below 30 mL/min.
• Cost & insurance: In the U.S., enoxaparin is frequently covered under standard pharmacy benefits; dalteparin may be preferred in the UK per NICE guidance because of national pricing agreements.
• Monitoring: Both agents can be monitored with anti‑Xa levels, but enoxaparin’s assay is more widely available in U.S. laboratories.

Clinical guidelines (ACOG 2023, RCOG 2022) state that either drug is acceptable for prophylaxis, and the decision often rests on patient preference, dosing convenience, and local formulary availability. If you have a history of heparin‑induced thrombocytopenia (HIT), both agents are contraindicated, and your provider will consider alternatives such as fondaparinux or low‑dose unfractionated heparin.

Safety considerations and contraindications for LMWH in pregnancy

LMWH is considered safe for both mother and fetus because it is a large molecule that does not cross the placenta. However, a few safety points deserve attention:

• Bleeding risk: Minor bruising at injection sites is common. Major bleeding (e.g., gastrointestinal, intracranial) is rare but warrants immediate medical attention.
• Spinal/epidural procedures: If you plan a combined spinal‑epidural (CSE) for labor analgesia, your anesthesiologist will ask you to hold the LMWH dose 12 hours prior to the procedure to reduce the risk of epidural hematoma.
• Renal impairment: Women with creatinine clearance < 30 mL/min should have dose reduced by 25‑30 % or switch to unfractionated heparin, which is easier to monitor.
• Allergy or HIT: Document any previous reaction to heparin products. If you develop new skin lesions or a platelet drop > 50 % after starting LMWH, contact your provider right away.
• Pregnancy‑specific concerns: LMWH does not increase the risk of congenital anomalies, preterm birth, or low birth weight, according to systematic reviews by the CDC and WHO.

Side effects are generally mild: injection‑site pain, occasional mild nausea, or transient elevation of liver enzymes (monitoring labs can catch this). If you experience severe abdominal pain, sudden shortness of breath, or black stools, seek emergency care—these could signal a serious bleed.

Monitoring protocols: labs, symptoms, and dose adjustments

Routine monitoring for prophylactic LMWH is less intensive than therapeutic dosing, but a few checkpoints keep you safe:

• Anti‑Xa level: For high‑risk or weight‑adjusted regimens, a single anti‑Xa draw 4‑5 hours after the dose can confirm you’re within the prophylactic range (0.2‑0.5 IU/mL). Repeat only if dose changes or renal function declines.
• Platelet count: Check at baseline and then every 4‑6 weeks. A drop below 150,000/µL or a > 50 % fall from baseline warrants evaluation for HIT.
• Renal function: Serum creatinine and estimated glomerular filtration rate (eGFR) should be measured each trimester, especially if you have pre‑existing kidney disease.
• Symptoms checklist: Keep a daily log of any new leg swelling, calf pain, chest discomfort, or unexplained bruising. Prompt reporting can catch a clot early.

Adjustments are typically made in the third trimester for women with BMI ≥ 35 kg/m² or those whose anti‑Xa level trends upward. For example, if your anti‑Xa reads 0.55 IU/mL at 30 weeks, your provider may increase the dosing interval to every other day or reduce the unit dose by 10 %.

Transitioning off LMWH: labor, delivery, and postpartum care

When you approach term, timing the last LMWH dose is crucial to balance clot prevention with bleeding risk during delivery. The general consensus from ACOG and NICE is:

• Vaginal delivery (spontaneous labor): Hold the last dose at least 12 hours before the estimated time of delivery. If labor starts unexpectedly, your obstetrician may give a short‑acting reversal (protamine sulfate) if bleeding becomes a concern.
• Cesarean delivery (planned): Hold LMWH 24 hours before the scheduled surgery. The anesthesiologist will confirm the timing to avoid epidural complications.
• Postpartum period: Restart LMWH 6‑12 hours after vaginal birth (once hemostasis is confirmed) and 12‑24 hours after C‑section. Continue prophylaxis for at least 6 weeks for high‑risk women, or 2‑4 weeks for moderate risk, per ACOG guidance.

Women with a lingering high‑risk score (e.g., ongoing thrombophilia) may be advised to stay on LMWH for up to 12 weeks postpartum, especially if breastfeeding, because the anticoagulant does not affect milk production.

During the postpartum window, many clinicians switch from daily injections to a once‑daily regimen for convenience, while still monitoring anti‑Xa levels if the dose is therapeutic. Once the postpartum prophylaxis period ends, a final evaluation of your VTE risk determines whether any long‑term anticoagulation is needed.

Lifestyle measures that complement LMWH

Medication is only one piece of the puzzle. Simple daily habits can further lower clot risk without adding drug side effects. Staying well‑hydrated—aim for at least 2 L of water a day—helps keep blood viscosity low. Light to moderate activity, such as walking or prenatal yoga, promotes venous return in the legs. If you have a desk job or spend long periods seated, stand up and stretch every hour; even a brief 2‑minute walk can make a difference.

Compression stockings, especially those graded 15‑30 mmHg, are recommended for women with BMI ≥ 30 kg/m² or a history of DVT. They gently squeeze the calf veins, encouraging blood flow back toward the heart. A balanced diet rich in fiber and low in excess sodium reduces swelling, while maintaining a healthy weight lessens the pressure on pelvic veins. Finally, avoid prolonged immobility during travel; if you must take a long flight, move your legs every 30 minutes and consider wearing compression socks.

Special considerations for renal impairment or HIT

Renal function naturally declines during pregnancy, but pre‑existing kidney disease demands extra vigilance. If your creatinine clearance falls below 30 mL/min, most guidelines (ACOG 2023, FDA labeling) suggest reducing the LMWH dose by 25‑30 % or switching to low‑dose unfractionated heparin, which can be monitored with activated partial thromboplastin time (aPTT). Regular renal panels each trimester help catch these changes early.

Heparin‑induced thrombocytopenia (HIT) is rare but serious. The hallmark is a platelet count drop of > 50 % occurring 5‑10 days after starting LMWH, often accompanied by new clot formation. If HIT is suspected, LMWH must be stopped immediately, and an alternative such as fondaparinux or a direct oral anticoagulant (if postpartum) may be used under specialist supervision. Documentation of HIT should travel with you to any future obstetric or surgical encounters.

LMWH and breastfeeding: impact on your baby

One common worry is whether LMWH will affect a nursing infant. Because LMWH does not cross into breast milk in measurable amounts, it is considered compatible with breastfeeding by the American Academy of Pediatrics (AAP) and the FDA. Mothers can safely continue their prophylactic regimen while nursing, and most babies experience no adverse effects.

Nevertheless, it’s good practice to mention your LMWH use at pediatric visits, just in case the infant shows unexplained bruising or bleeding—rare events that could be unrelated but worth monitoring. If you ever need to pause LMWH for a procedure, discuss with both your obstetrician and pediatrician to coordinate timing.

From our medical team: “If you’re prescribed LMWH, treat it like any other daily medication—set a reminder, keep a log of injection sites, and bring your anti‑Xa results to each prenatal visit. The goal is to keep you clot‑free without unnecessary interruptions, especially around delivery.”

Myth vs. fact

Myth: “If I take LMWH, I’ll have to stop it completely for the entire pregnancy.”

Fact: LMWH is typically continued throughout pregnancy for moderate‑to‑high risk women, only pausing briefly (12‑24 hours) before labor or a scheduled C‑section.

Myth: “LMWH can cause birth defects because it circulates in my blood.”

Fact: LMWH is a large molecule that does not cross the placenta, and extensive research from the CDC and WHO shows no increase in fetal malformations.

Myth: “I need regular blood tests to check LMWH levels, just like with warfarin.”

Fact: Routine anti‑Xa monitoring is only needed for high‑dose or weight‑adjusted regimens; most prophylactic doses are fixed and don’t require frequent labs.

Key takeaways

• Pregnancy naturally increases clot risk; additional factors like prior VTE, obesity, and multiple gestation raise it further.
• Use the RCOG risk‑score tool to categorize yourself as low, moderate, or high risk; recalculate each trimester.
• For moderate risk, start enoxaparin 40 mg or dalteparin 5,000 U once daily at 12‑14 weeks; high risk often requires twice‑daily dosing.
• Weight‑adjusted dosing and third‑trimester increases may be needed for BMI ≥ 35 kg/m²; anti‑Xa levels guide adjustments.
• Hold the last LMWH dose 12 hours before vaginal delivery or 24 hours before a planned C‑section, then resume postpartum for 6‑12 weeks.
• Monitor for bruising, bleeding, or platelet drops, and keep an open line with your obstetric team for any new symptoms.
• Complement medication with hydration, gentle movement, and graduated compression stockings to further lower risk.

Frequently asked questions

What is the recommended LMWH dose for pregnant women at high risk of clotting?

High‑risk women (≥ 4 points on the RCOG score) usually receive enoxaparin 40 mg subcutaneously twice daily or dalteparin 5,000 units twice daily, starting as early as 10‑12 weeks gestation.

How is the blood clot risk score calculated during pregnancy?

The RCOG tool assigns points for prior VTE, known thrombophilia, obesity, age, multiple gestation, immobilization, planned C‑section, and active inflammatory disease; totals of 0‑1 are low, 2‑3 moderate, and 4 or more high risk.

Can I take LMWH throughout my entire pregnancy?

Yes—most guidelines advise continuing prophylactic LMWH until just before labor (12 hours for vaginal, 24 hours for C‑section) and then restarting postpartum for several weeks.

Are there any side effects of LMWH for pregnant women?

Common side effects include mild injection‑site bruising or pain; rare but serious issues are major bleeding or heparin‑induced thrombocytopenia, which require immediate medical attention.

When should I stop LMWH before going into labor?

Hold the final dose at least 12 hours before the expected onset of spontaneous labor, or 24 hours before a scheduled cesarean, to reduce bleeding risk.

Do I need blood tests to monitor LMWH levels while pregnant?

Routine anti‑Xa testing is only needed for high‑dose or weight‑adjusted regimens; most prophylactic doses are fixed and do not require regular blood work.

Can I exercise while on LMWH?

Yes—moderate, low‑impact activities such as walking, swimming, or prenatal yoga are safe and actually help prevent clots by improving circulation. Avoid high‑impact or contact sports that increase injury risk.

What should I do if I miss a dose of LMWH?

If you realize a dose was missed, take it as soon as you remember unless it’s less than 12 hours until the next scheduled dose. In that case, skip the missed dose and resume your regular schedule; do not double up, and inform your provider at your next visit.

When to call your doctor

If you notice any of the following, seek medical care right away: sudden calf swelling or pain, unexplained bruising, chest pain or shortness of breath, dark stools, or a rapid drop in platelet count. This article is for information only and does not replace personalized medical advice—always discuss your individual risk and treatment plan with your obstetric provider.

References

1. American College of Obstetricians and Gynecologists. “Prevention and Management of VTE in Pregnancy.” ACOG Practice Bulletin No. 196, 2023.
2. Royal College of Obstetricians and Gynaecologists. “VTE Risk Assessment and Prophylaxis in Pregnancy.” Green‑top Guideline No. 37a, 2022.
3. National Institute for Health and Care Excellence. “Venous thromboembolism in pregnancy: prevention and management.” NICE Clinical Guideline 157, 2021.
4. Centers for Disease Control and Prevention. “Pregnancy‑Associated Venous Thromboembolism.” Updated 2022.
5. World Health Organization. “WHO recommendations for prevention and treatment of VTE in pregnancy.” 2020.
6. Mayo Clinic. “Low‑molecular‑weight heparin (LMWH) in pregnancy.” Patient education, 2023.
7. National Health Service (UK). “Blood clots in pregnancy.” Clinical guidance, 2022.
8. Society of Obstetricians and Gynaecologists of Canada. “Anticoagulation in Pregnancy.” 2023.
9. American Academy of Pediatrics. “Breastfeeding and Medication Use.” Policy Statement, 2021.
10. U.S. Food and Drug Administration. “Enoxaparin Sodium Injection (Lovenox) Prescribing Information.” Updated 2023.